Decreased immunity to a greater or lesser extent is a problem for 70% of the population. Primary or acquired immunodeficiency is the cause of an increasing number of chronic infectious, autoimmune, and oncological diseases. Weak immunity leads to chronic disease, increased complications and even increased mortality.
The state of immunity is affected by both external factors - environmental pollution by various chemical emissions, and internal causes - uncontrolled intake of drugs, the addition of various preservatives to food, processing of products to extend shelf life, plastic packaging, etc.
Doctors around the world have noted an increase in cancer - benign and malignant. A decrease in immunity is one of the causes of malignancy of formations and their metastasis. Chemo and radiation therapy, hormone and antibiotic therapy contribute to the deepening of changes in immunological reactivity. After their completion, the so-called immunosuppressive train remains, which lasts from 3 weeks to 2-3 months.
For the correction of the immune system in secondary immunodeficiencies, immunomodulators are increasingly being used. The most effective and adapted to the human body are immunomodulators obtained from bacteria of the normal intestinal flora. They are natural stimulants of the immune system, most of which are located in the intestinal walls. One of these natural immunomodulators is Blastomunil. It is obtained from lactobacillus cells in the form of a lyophilized lysate of these bacteria.
The active ingredient of this one-of-a-kind drug is blastolen, a peptidoglycan isolated from the cell wall of the lactic acid bacterium Lactobacillus delbrueсkii. Lactobacilli on their surface contain receptors corresponding to macrophage receptors - they play a major role in the activation of macrophages.
Blastomunil - an immunomodulator that stimulates cellular and humoral immunity, the activity of cytokines. The drug increases the number of leukocytes in peripheral blood at a reduced level, mainly neutrophils and T and B lymphocytes, enhances phagocytosis, reduces the level of circulating immune complexes, normalizes the content of class M and G immunoglobulins in the blood plasma, and is an inducer of interferon IL-1 and IL-2, which play a major role in the regulation of the T-cell immune response, differentiation and activation of B and NK cells, improves the endocrine function of the thymus gland. Blastomunil improves blood microcirculation in tissues, stimulates the processes of their regeneration, has antibacterial, antiviral effects, exhibits antitumor and antimetastatic effects, reduces the severity of adverse reactions during radiation therapy. Blastomunil normalizes immune function and reduces inflammatory processes in affected organs by increasing the activity of cytokines, lowering the level of circulating immune complexes, and normalizing the concentration of immunoglobulins in blood serum.
Blastolen has long been used in the complex anti-inflammatory and antiviral therapy of acute and chronic diseases of the bronchi and lungs; in the surgical treatment of oncological and other diseases of the abdominal cavity and chest, genitals, breast, for the prevention of postoperative complications.
Blastomunil has:
- Immunomodulating action: Normalizes indicators of humoral and cellular immunity and cytokine activity.
- Anti-inflammatory and antiviral action.
- With complex anti-inflammatory and antiviral therapy acute and chronic diseases of the bronchi and lungs, to increase the effectiveness of treatment in debilitated patients and the elderly, with rheumatoid lesions of the joints.
- Hemoprotective function: protects leukopoiesis, especially with neutropenia, increases the level of leukocytes in secondary leukopenia, leukopenia of various origins.
- Improves blood microcirculation in tissues, stimulates the processes of their regeneration.
- Radioprotective action: In acute and chronic radiation injuries, especially under conditions of prolonged action of low-intensity radiation in low doses, with chemo- and radiation therapy of cancer patients, their adverse reactions are reduced.
- Antitumor and antimetastatic action;
- Antibacterial action - in the surgical treatment of oncological and other diseases of the abdominal cavity and chest, genitals, mammary gland, for the prevention of postoperative complications and accelerate the recovery of patients.
The pronounced immunomodulatory property of Blastomunil has been widely used in the clinic as a remedy for diseases accompanied by immunodeficiency and leukopenia, namely during chemotherapy and radiation therapy of cancer patients in order to increase the antitumor effectiveness of cytostatics and reduce their toxic effects.
Using Blastomunil in the complex treatment of cancer patients, the drug is started to be administered at a dose of 0,6 mg subcutaneously 1-3 days before the start of the first course of chemotherapy or in conjunction with radiation therapy, before the operation together with antibiotics. At least 3 injections are necessary for the course of treatment. In case of high doses, it is necessary to increase the course to 5 injections. The interval between injections is 5-7 days. Conducting immunotherapy courses during antitumor treatment, especially in combination with the surgical removal of large tumors and in the first 3 months after surgery, significantly reduce mortality and increase the percentage of patients recovering.
During remission, Blastomunil is used after the main treatment methods with removal of the tumor, especially in the first 3 years. Conducting immunotherapy with Blastomunil is aimed at the prevention of metastases and relapses.
Indications for the appointment of blastomunyl are severe bacterial and viral infections that occur with severe intoxication. It is necessary to prescribe Blastomunil as part of a comprehensive etiopathogenetic treatment only after removing the patient from bacterial toxic shock.
The use of Blastomunyl in the complex therapy of infectious diseases simultaneously with etiotropic drugs can significantly increase the effectiveness of treatment, reduce the number of drugs used, especially antibiotics, and prevent the transition to a chronic form.
A special group of indications are diseases of the elderly. At an older age, disturbances in the activity of mononuclear phagocytes appear. In case of infections in the elderly, leukocytosis is less pronounced, cell accumulation in places of inflammatory processes is weakened, the response to the action of inflammatory mediators is reduced, the ability of macrophages to lyse bacteria collected during phagocytosis is reduced.
Also, in people aged 65 years and older, the cytotoxic activity of blood monocytes in relation to tumor cells is partially reduced. Their monocytes secrete weaker IL-1. The defectiveness of the production of anti-inflammatory cytokines by macrophages is indicated by a less pronounced increase in temperature with the development of infection in the elderly.
With age, the ability of macrophages to respond by activation to appropriate inducers, including cytokines, also decreases. In such cases, for the treatment of the elderly, Blastomunil is used in a dose of 0,6 mg once every 1 days, 10 injections per course.
Blastomunil is used for acute and chronic radiation injuries, especially under conditions of prolonged exposure to low-intensity radiation in small doses.
Blastomunil is also prescribed for trophic ulcers, chronic streptoderma, furunculosis.
For prophylactic purposes, 1 injection of Blastomunil in a recommended dose of 0,6 mg 1-2 times a year is enough to maintain the immune status and prevent morbidity.
The clinical experience of Blastomunyl is well described in the work of the team of the Scientific-Biotechnological Center Enzifarm LLC, the authors - Volokhovskaya V.A., Vasiliev V.I. and Nagorny O.V. “Blastomunil. A natural immunomodulator isolated from lactic acid bacteria cells. ” You can read the electronic version on our website. We give only some excerpts from this work “In scientific papers (Slizhenko Yu. Et al., 2005, 2006; Mosienko V. et al. 2006, 2007) and reports of regional oncological dispensaries, it was shown that the use of Blastomunil in the complex treatment of tumor disease in almost of all patients was accompanied by a marked decrease in inflammatory reactions and pain, normalization of body temperature, a decrease in cough, dyspeptic manifestations, an improvement in the general well-being of patients, an increase in the Karnovsky index, and also a decrease in the number of purulent-septic postoperative non-surgical complications, increased antitumor efficacy of chemo- and radiation therapy compared with the control group of patients. Blastomunil did not create any serious adverse reactions, did not show a sensitizing and allergenic effect, with the exception of a local reaction in 3% of patients in the form of hyperemia and a slight increase (up to 38 ° C) in body temperature, which independently disappeared during the day. ”
“The influence of Blastomunyl on the number of leukocytes in peripheral blood was evaluated by indicators of the cellular and humoral links of immunity and cytokine activity. So before treatment, the level of leukocytes in patients receiving blastomunil was significantly lower compared with the control group. In the middle of treatment, the number of leukocytes in patients of the main group for all treatment options was significantly higher than in control patients. These data indicate the leukostimulating properties of the immunomodulator on the background of chemo- and radiation therapy.
Such an increase in the absolute value of the level of leukocytes in the blood (in percent) was the highest in those patients who were administered Blastomunil 1-3 days before the main treatment. In patients to whom the drug was administered after the start of the main treatment, the blood counts were lower, but significantly higher than in the control group. "
The drug is administered subcutaneously or intramuscularly. The daily dose for adults is 0,6 mg; at the same time, the interval between injections is observed - 5-7 days. A single course of treatment requires only 3-5 injections. If necessary, after 3-6 and 12 months can be repeated courses of treatment with Blastomunil.
Immunotherapy of cancer patients using the Blastomunil immunomodulator is an essential support for chemotherapy and radiation therapy. The drug acts on neoplasm cells indirectly - through the activation of the immune system as a whole and directly - through macrophages, T-lymphocytes, killer cells and cytokines, stimulates non-specific resistance mechanisms, helps preserve the endocrine function of the thymus against the background of combined and complex treatment of malignant tumors and bronchial pulmonary diseases.
The inclusion of Blastomunil in the treatment of cancer and other diseases as a support drug significantly increases the effectiveness of traditional methods of treatment, accelerates the start of rehabilitation, prolongs the period of remission, increases the 5-year overall and relapse-free survival, makes it possible to conduct a full course of chemo- and radiation therapy, reduces the number of exacerbations, reduces the length of hospital stay for patients.
With the advanced stages of tumor disease, Blastomunil significantly improves the quality of life, reduces pain, and prolongs remission with combined treatment.
Blastomunyl is a natural immunomodulator that can change immune reactivity depending on its initial state: increase or decrease immunity.
The use of Blastomunil improves the quality of life of patients receiving antibiotics, chemotherapy or radiation therapy, minimizes the risk of complications and infections. Convenient regimens and regimen of administration allow using the drug as an accompanying therapy for the prevention of toxic effects after chemotherapy, as well as for the treatment of immunosuppressive conditions of various origins. Blastomunil has prospects for successful use in the complex treatment of severe infectious diseases, such as herpes, hepatitis, AIDS, syphilis, tuberculosis. The drug does not have a local irritant, embryotoxic, mutagenic and teratogenic effects.
You can buy Blastomunil in our online store
![]() |
![]() |
|
Blastomunil packaging 5 vials | Blastomunyl vial 0,6 mg |
Doctors of the Kiev Center for Fungotherapy, Bioregulation and Ayurveda will advise you on the correct use of Blastomunil
Waiting for you
Working hours of the center: Mon-Fri: from 9-00 to 18-00 Sat: from 9-00 to 17-00
tel: (097) 231-74-44, (050) 331-74-44, (063) 187-78-78
+38(098) 583-85-85 (Viber), + 38 (093) 688-25-88 (WhatsApp, Telegram)
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
The book "Blastomunyl natural immunomodulator isolated from cells of lactic acid bacteria"
Contents:
- Introduction
- The history of the drug Blastomunil
- Pharmacological properties of blastomunyl
- The mechanism of action of blastomunyl
- Clinical experience
- The use of blastomunil in the treatment of patients with breast cancer
- Blastomunil in the complex treatment of patients with ovarian cancer
- Blastomunil in the complex treatment of cervical cancer
- Blastomunil in the complex treatment of patients with esophageal cancer and gastrophagous cancer
- Treatment of mastopathy using Blastomunil
- The use of blastomunyl in the treatment of acute pneumonia and chronic obstructive bronchitis
- Blastomunil in the complex treatment of pulmonary tuberculosis in combination with AIDS
- The use of blastomunyl in dermatovenerology
- Indications for use and Blastomunil use strategy
- Prevention of generalization of the infectious process
- Conclusions
- References
Read the whole book here to register: